Study: NCT01074008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450
Description: 50 mg capsules co-administered with ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450
Description: 50 mg capsules co-administered with ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450
Description: 50 mg capsules co-administered with ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-072
Description: 50 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-072
Description: 50 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-072
Description: 50 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: 400 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: 400 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100 mg capsules co-administered with ABT-450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100 mg capsules co-administered with ABT-450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100 mg capsules co-administered with ABT-450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2a
Description: Syringe, 180 µg/0.5 mL for subcutaneous injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2a
Description: Syringe, 180 µg/0.5 mL for subcutaneous injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2a
Description: Syringe, 180 µg/0.5 mL for subcutaneous injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2a
Description: Syringe, 180 µg/0.5 mL for subcutaneous injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2a
Description: Syringe, 180 µg/0.5 mL for subcutaneous injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2a
Description: Syringe, 180 µg/0.5 mL for subcutaneous injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2a
Description: Syringe, 180 µg/0.5 mL for subcutaneous injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2a
Description: Syringe, 180 µg/0.5 mL for subcutaneous injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon alpha-2a
Description: Syringe, 180 µg/0.5 mL for subcutaneous injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: 200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level